HHS issues RFI for Part D '$2 drugs' on some widely-used prescriptions

by Roy Edroso on Oct 10, 2024
Adding to its other pioneering prescription drug programs under Medicare, the Biden administration announced on Wednesday it would issue a request for information (RFI) on a potential “Medicare $2 Drug List Model” that would make some much-used drugs for hypertension, high cholesterol and other common conditions available to Part D beneficiaries for a couple of bucks.
 
The Model would be administered by the Center for Medicare and Medicaid Innovation (CMMI) and would “standardize cost sharing for low-cost generics through a new, easy-to-understand option for people with Medicare Part D enrolled in a participating plan and their health care providers,” CMMI says.
 
The 270 potential drugs (including various doses and formulations) listed by CMMI include anti-depressants escitalopram and bupropion; the antipsychotic lithium; blood pressure medications metoprolol, hydrochlorothiazide and amlodipine; antibiotics penicillin and amoxicillin; statins atorvastatin and simvastatin; the antifungal Fluconazole; and the blood-thinner Warfarin.
 
CMS and CMMI cite a mandate from President Biden’s Oct. 14, 2022, Executive Order on prescription drug prices, which does not specify a $2.00 initiative, and HHS Secretary Xavier Becerra’s Feb. 14, 2023, report, which calls for a “Medicare High-Value Drug List” pilot “allowing Part D Sponsors to offer a Medicare-defined standard set of approximately 150 high-value generic drugs with a maximum co-payment of $2 for a month’s supply, applying across all phases of Part D coverage up to the out-of-pocket limit.”
 
The program would be voluntary for Part D sponsors, CMS says, and “pending further development, could start as early as January 2027.”
 
The RFI is here; it lists “primary areas of interest” that include: “Drug List Development Process” and “Maximizing Plan Participation,” among others. Responses are due by Dec. 9, 2024.
 
 
Blog Tags: CMS
The information contained herein was current as of the publication date. © Copyright DecisionHealth, all rights reserved. Electronic or print redistribution without prior written permission of DecisionHealth is strictly prohibited by federal copyright law.